Quest Diagnostics received New York approval for its Haystack MRD test for detecting residual or recurring disease across a range of solid tumors, with the company stating the authorization enables testing in all 50 states and Washington, D.C. Quest launched the assay late in 2024 and pointed to clinical utility data including The New England Journal of Medicine study findings. The test is designed to support earlier detection of residual disease, with Quest highlighting that it can identify clinical complete response earlier than traditional imaging in cited study results. The regulatory clearance broadens real-world access and may drive adoption among oncologists looking for actionable MRD signals. For liquid biopsy developers, the decision adds another example of MRD assays moving into routine care pathways with payor and guideline implications likely to follow as evidence accumulates. Key next steps for the platform will be expanding coverage by additional indications and translating assay performance into standardized treatment response workflows.